A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Clinical trial NCT05958199 · SUSPENDED

Trial details

NCT number: NCT05958199
Sponsor: NextPoint Therapeutics, Inc.
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Malignant Neoplasm

Start date: 2023-07-21
Primary completion: 2025-09-20
Enrollment: 131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.